$MCAA
Mountain & Co I Acquisition Corp Stock $mcaa

$mcaa Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000110465924064383 Filed on May 23, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$375.3K	$2.403M	$133.2K
YoY Change	181.74%	84.35%	-10.37%
Operating Profit		-$2.403M
YoY Change		84.36%
Interest Expense	$1.409M	$7.111M	$1.674M
YoY Change	-15.8%	181.1%	162421.36%
% of Operating Profit
Other Income/Expense, Net		$7.111M	$0.00
YoY Change		181.1%	-100.0%
Pretax Income	$1.034M	$4.708M	$1.541M
YoY Change	-32.88%	283.94%	-842.18%
Income Tax
% Of Pretax Income
Net Earnings	$1.034M	$4.708M	$1.541M
YoY Change	-32.88%	283.94%	-842.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.06	$0.25	$0.06
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.54K	$68.54K	$34.19K
YoY Change	100.47%	100.47%	-88.75%
Cash & Equivalents	$68.54K		$34.19K
Short-Term Investments
Other Short-Term Assets	$1.310K	$1.310K	$347.9K
YoY Change	-99.62%	-99.62%	-19.97%
Inventory
Prepaid Expenses	$1.307K		$347.9K
Receivables	$600.0K		$257.5K
Other Receivables
Total Short-Term Assets	$669.8K	$669.8K	$639.5K
YoY Change	4.74%	4.74%	-36.96%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$129.3M	$129.3M	$239.4M
YoY Change	-46.01%	-46.01%	0.92%
Total Long-Term Assets	$129.3M	$129.3M	$239.4M
YoY Change	-46.01%	-46.01%	0.92%
TOTAL ASSETS
Total Short-Term Assets	$669.8K	$669.8K	$639.5K
Total Long-Term Assets	$129.3M	$129.3M	$239.4M
Total Assets	$129.9M	$129.9M	$240.1M
YoY Change	-45.87%	-45.87%	0.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$600.0K	$600.0K
YoY Change
Accrued Expenses	$1.872M	$1.872M	$579.6K
YoY Change	223.02%	223.02%	392.9%
Deferred Revenue
YoY Change
Short-Term Debt	$3.778M	$3.778M	$118.8K
YoY Change	3079.05%	3079.05%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.804M	$6.804M	$830.4K
YoY Change	719.33%	719.33%	234.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.050M	$8.050M	$8.050M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$8.050M	$8.050M	$8.050M
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.804M	$6.804M	$830.4K
Total Long-Term Liabilities	$8.050M	$8.050M	$8.050M
Total Liabilities	$14.85M	$14.85M	$8.880M
YoY Change	67.26%	67.26%	7.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.78M		-$8.241M
YoY Change	79.39%		18.8%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.78M	$115.1M	-$8.241M
YoY Change
Total Liabilities & Shareholders Equity	$129.9M	$129.9M	$240.1M
YoY Change	-45.87%	-45.87%	0.76%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	$1.034M	$4.708M	$1.541M
YoY Change	-32.88%	283.94%	-842.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$23.09K	-$84.48K	-$33.62K
YoY Change	-31.32%	-68.67%	-96.87%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$300.0K	$117.3M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$300.0K	$117.3M	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.0K	-117.2M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-23.09K	-84.48K	-33.62K
Cash From Investing Activities	-300.0K	117.3M	0.000
Cash From Financing Activities	300.0K	-117.2M	0.000
Net Change In Cash	-23.09K	34.35K	-33.62K
YoY Change	-31.32%	-112.74%	-111.06%
FREE CASH FLOW
Cash From Operating Activities	-$23.09K	-$84.48K	-$33.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://www.Mountainacquisitioncorp.com/20231231#SponsorMember
CY2023Q4	us-gaap	Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://www.Mountainacquisitioncorp.com/20231231#SponsorMember
CY2022Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://www.Mountainacquisitioncorp.com/20231231#SponsorMember
CY2023Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://www.Mountainacquisitioncorp.com/20231231#SponsorMember
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001856995
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	mcaau	Threshold Business Days For Redemption Of Public Shares ThresholdBusinessDaysForRedemptionOfPublicShares	P10D
CY2023	mcaau	Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination	P2D
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q4	mcaau	Stockholders Percentage Of Vote For Certain Actions StockholdersPercentageOfVoteForCertainActions	0.006666
CY2023Q4	mcaau	Stockholders Percentage Of Vote For Certain Actions StockholdersPercentageOfVoteForCertainActions	0.006666
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41021
CY2023	dei	Entity Registrant Name EntityRegistrantName	MOUNTAIN & CO. I ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4001 Kennett Pike, Suite 302
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Wilmington
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	DE
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19807
CY2023	dei	City Area Code CityAreaCode	302
CY2023	dei	Local Phone Number LocalPhoneNumber	273-0765
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	132899613.44
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Cash Cash	68536
CY2022Q4	us-gaap	Cash Cash	34186
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	600000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	257478
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1307
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	347876
CY2023Q4	us-gaap	Assets Current AssetsCurrent	669843
CY2022Q4	us-gaap	Assets Current AssetsCurrent	639540
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	129271658
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	239430719
CY2023Q4	us-gaap	Assets Assets	129941501
CY2022Q4	us-gaap	Assets Assets	240070259
CY2023Q4	mcaau	Accrued Offering Costs AccruedOfferingCosts	1872078
CY2022Q4	mcaau	Accrued Offering Costs AccruedOfferingCosts	579550
CY2023Q4	mcaau	Payable Into Trust Account Current PayableIntoTrustAccountCurrent	600000
CY2023Q4	mcaau	Due To Related Party DueToRelatedParty	553841
CY2022Q4	mcaau	Due To Related Party DueToRelatedParty	132000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3777666
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	118833
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6803585
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	830383
CY2023Q4	mcaau	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000
CY2022Q4	mcaau	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000
CY2023Q4	us-gaap	Liabilities Liabilities	14853585
CY2022Q4	us-gaap	Liabilities Liabilities	8880383
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14784317
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8241418
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783742
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8240843
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129941501
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240070259
CY2023	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2402898
CY2022	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	1303408
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2402898
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1303408
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	7111024
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	2529689
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7111024
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2529689
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4708126
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1226281
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6936405
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2530719
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1226281
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8240843
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	11251025
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4708126
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14783742
CY2023	us-gaap	Profit Loss ProfitLoss	4708126
CY2022	us-gaap	Profit Loss ProfitLoss	1226281
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7111024
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2529689
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-346569
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-433242
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	342522
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-18522
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	600000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1292527
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	461972
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	421841
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	120000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84483
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-269672
CY2023	mcaau	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	3540000
CY2023	mcaau	Proceeds From Cash Withdrawn From Trust Account ProceedsFromCashWithdrawnFromTrustAccount	120810086
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	117270086
CY2023	mcaau	Payments For Redemptions PaymentsForRedemptions	120810086
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3658833
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-117151253
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34350
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-269672
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34186
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	303858
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68536
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34186
CY2023	mcaau	Accretion Of Class Common Stock Subject Redemption To Redemption Value AccretionOfClassCommonStockSubjectRedemptionToRedemptionValue	11251025
CY2022	mcaau	Accretion Of Class Common Stock Subject Redemption To Redemption Value AccretionOfClassCommonStockSubjectRedemptionToRedemptionValue	2530719
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND LIQUIDITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Mountain & Co. I Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on April 16, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses or entities (the “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023 relates to the Company’s formation and the initial public offering (“IPO”) described below. The Company will not generate any operating revenues at the earliest until after the completion of its initial Business Combination. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s sponsor is Mountain & Co. I Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s IPO was declared effective on November 4, 2021 (the “Effective Date”). On November 9, 2021, the Company consummated its IPO of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit, which is discussed in Note 3 (the “Public Offering”) and the sale of 12,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering. On November 12, 2021, the underwriters exercised their full over-allotment option, resulting in an addition 3,000,000 units purchased and $30,000,000 in additional gross proceeds for aggregate units purchased of 23,000,000 and aggregate gross proceeds of $230,000,000 from both the IPO and over-allotment option exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Transaction costs related to the IPO and the exercise of the over-allotment option amounted to $13,406,427 consisting of $4,600,000 of underwriting commissions, $8,050,000 of deferred underwriting fees and $756,427 of other cash offering costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company must consummate an initial Business Combination with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the trust account (as defined below) (excluding the amount of any deferred underwriting discount held in trust) at the time of its signing a definitive agreement in connection with the initial Business Combination. However, the Company will only complete such Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company does not believe that its anticipated principal activities will subject them to the Investment Company Act. To this end, the proceeds held in the trust account may only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), the Company intends to avoid being deemed an “investment company” within the meaning of the Investment Company Act. The IPO offering is not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of its obligation to provide holders of the Company’s Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of public shares if the Company does not complete its initial Business Combination by November 9, 2024 or (B) with respect to any other provision relating to the rights of holders of Class A ordinary shares; or (iii) absent its completing an initial Business Combination within 15 months from the closing of this offering (or up to 18 months from the closing of this offering if we extend the period of time to consummate a Business Combination), the return of the funds held in the trust account to the public shareholders as part of the redemption of the public shares. If the Company does not invest the proceeds as discussed above, the Company may be deemed to be subject to the Investment Company Act. Although the Company expects to enter into an agreement with a target company for a business combination no later than 18 months after, and to consummate a business combination prior to the 24 month anniversary of, its IPO, should the Company be unable to do so, the Company intends to instruct Continental Stock Transfer & Trust Company, the trustee with respect to the trust account, to liquidate the U.S. government securities or money market funds held in the trust account and thereafter to hold all funds in the trust account in cash until the earlier of consummation of the Company’s business combination or liquidation, to mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act. If the Company were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which the Company has not allotted funds and may hinder the ability to complete a Business Combination. If the Company has not consummated the initial Business Combination within the required time period, the public shareholders may receive only approximately $10.30 per public share, or less in certain circumstances, on the liquidation of the trust account and the warrants will expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the IPO on November 9, 2021, and subsequent close of the over-allotment option exercise on November 12, 2021, a total of $236,900,000, comprised of $225,400,000 of the net proceeds from the IPO, including $8,050,000 of the underwriters’ deferred discount, and $11,500,000 of the proceeds of the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of the initial Business Combination either (i) in connection with a general meeting called to approve the initial Business Combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement or whether the Company were deemed to be a foreign private issuer (which would require a tender offer rather than seeking shareholder approval under SEC rules). The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of <span style="-sec-ix-hidden:Hidden_eCeE5e1O10SlsY60iYlpGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.30 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The ordinary shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If the Company has not consummated an initial Business Combination by November 9, 2024, the proceeds then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), will be used to fund the redemption of its public shares, as further described herein. Any redemption of public shareholders from the trust account will be effected automatically by function of the amended and restated memorandum and articles of association prior to any voluntary winding up. If the Company were required to wind up, liquidate the trust account and distribute such amount therein, pro rata, to its public shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions of the Companies Act. In that case, investors may be forced to wait beyond November 9, 2024 before the redemption proceeds of the trust account become available to them, and they receive the return of their pro rata portion of the proceeds from the trust account. The Company has no obligation to return funds to investors prior to the date of the redemption or liquidation unless, prior thereto, the Company consummated its initial Business Combination or amend certain provisions of the amended and restated memorandum and articles of association, and only then in cases where investors have sought to redeem their Class A ordinary shares. Only upon the redemption or any liquidation will public redemptions be entitled to distributions if the Company does not complete its initial Business Combination and do not amend certain provisions of the amended and restated memorandum and articles of association. The amended and restated memorandum and articles of association will provide that, if the Company winds up for any other reason prior to the consummation of its initial Business Combination, the Company will follow the foregoing procedures with respect to the liquidation of the trust account as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_Ibnw524-DE61LT_ZVgASxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, subject to applicable Cayman Islands law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their Founder Shares and public shares in connection with the completion of the initial Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the public shares if the Company has not consummated an initial Business Combination within the Combination Period or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity; (iii) waive their rights to liquidating distributions from the trust account with respect to their Founder Shares if the Company fails to complete its initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame; and (iv) vote any Founder Shares held by them and any public shares purchased during or after the Public Offering (including in open market and privately-negotiated transactions) in favor of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2023, the Company held an extraordinary general meeting of shareholders, where our shareholders approved a special resolution (the “Extension Amendment Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from February 9, 2023 to November 9, 2023 (the “Extension”), the date by which the Company must consummate an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote to approve the Extension Amendment Proposal, shareholders holding 10,784,962 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the trust account. As a result, approximately $113.0 million (approximately $10.48 per share) was removed from the trust account to pay such redeeming holders, representing 46.9% of the public shares. 53.1% of the public shares issued in our IPO remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the Extension, the Sponsor agreed to advance to the Company (i) $420,000 plus (ii) $420,000 for each subsequent calendar month commencing on March 9, 2023, and on the 9th day of each subsequent month, or portion thereof, that the Company requires to complete a Business Combination, to be deposited in the trust account on or before the 9th day of each calendar month, until November 9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2023, the Company issued a promissory note (the “Note”) in the principal amount of up to $3,780,000 to the Sponsor, in connection with the Extension. The Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company’s initial business combination, or (b) the date of the liquidation of the Company. At the option of the Sponsor, up to $1,500,000 of the loan would be convertible into warrants identical to the Company’s private placement warrants, at $1.00 per warrant. Any amendments to the Note and the loan may be made with the written consent of the Sponsor and the Company. For example, if we determine that we no longer expect to complete a business combination within the prescribed time frame, the Sponsor and the Company may agree to discontinue such loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Sponsor has deposited seven monthly payments of $420,000 or $2,940,000 in total in connection with the Extension and under the Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2023, the Company held an extraordinary general meeting of shareholders, where our shareholders approved a special resolution (the “Second Extension Amendment Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from November 9, 2023 to March 9, 2024 (the “Second Extended Date”), the date by which the Company must consummate an initial business combination (the “Second Extension”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote to approve the Second Extension Amendment Proposal, shareholders holding 701,973 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the trust account. As a result, approximately $7.8 million (approximately $11.05 per share), was removed from the trust account to pay such redeeming holders, representing 49.9% of the public shares in the aggregate. 50.1% of the public shares issued in our IPO remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the Second Extension, the Sponsor agreed to, in its discretion, advance to the Company (i) $300,000 plus (ii) $300,000 for each subsequent calendar month commencing on October 9, 2023, and on the 9th day of each subsequent month, or portion thereof, that the Company requires to complete a Business Combination, to be deposited in the trust account on or before the 9th day of each calendar month, until the Second Extended Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2023, the Company amended and restated that certain promissory note, dated February 6, 2023 (the “Amended and Restated Note”) previously issued by the Company to the Sponsor in respect of such advances and the Sponsor has waived any and all rights to the monies held in the trust account with respect to those advances. The Amended and Restated Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company’s initial business combination, or (b) the date of the liquidation of the Company. At the option of the Sponsor, up to $1,500,000 of the loan would be convertible into warrants identical to the Company’s private placement warrants, at $1.00 per warrant. Any amendments to the Amended and Restated Note and the loan may be made with the written consent of the Sponsor and the Company. For example, if we determine that we no longer expect to complete a business combination within the prescribed time frame, the Sponsor and the Company may agree to discontinue such loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, a payment of $300,000 has been made to the Trust Account in connection with the Second Extension and under the Note. As of December 31, 2023, the Sponsor had not made additional payments in connection with the Second Extension due on November 9, 2023 and December 9, 2023, respectively. The Sponsor had sole discretion whether to make such payments. However, payments of $300,000 for each calendar month commencing September 2023 and ending February 2024, or $1.2 million in the aggregate, were deposited into the Trust Account. (See Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.30 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.30 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for the initial Business Combination and redemptions could be reduced to less than $10.30 per public share. In such event, the Company may not be able to complete the initial Business Combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Liquidity, Capital Resources and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2023, the Company had $68,536 in operating cash and a working capital deficit of $6,133,742.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs up to December 31, 2023 have been satisfied through the payment of certain offering costs by Sponsor of $25,000 (see Note 5) for the Founder Shares and the loan under an unsecured promissory note from the Sponsor of $500,000 (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as defined below (see Note 5). As of December 31, 2023 and 2022, there were no amounts outstanding under any Working Capital Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Account Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that the Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. In addition, the Company has until November 9, 2024 to consummate a Business Combination. Management considers that liquidity and capital resources available might not be sufficient to operate through November 9, 2024. Also, it is uncertain that the Company will be able to consummate a Business Combination by this date. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management has determined that the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, in addition to potential liquidity and capital shortage raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. On May 5, 2023, the World Health Organization declared that COVID-19 no longer constitutes a public health emergency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2023	mcaau	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2021Q4	mcaau	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	23000000
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	230000000
CY2021Q4	mcaau	Transaction Costs TransactionCosts	13406427
CY2021Q4	mcaau	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	4600000
CY2021Q4	mcaau	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000
CY2021Q4	mcaau	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	756427
CY2023	mcaau	Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount	0.80
CY2023	mcaau	Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination	0.50
CY2023	mcaau	Maturity Period Of Investments In Money Market Funds MaturityPeriodOfInvestmentsInMoneyMarketFunds	P185D
CY2023	mcaau	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1
CY2023	mcaau	Minimum Period To Complete Business Combination From Closing Of Offering MinimumPeriodToCompleteBusinessCombinationFromClosingOfOffering	P15M
CY2023	mcaau	Maximum Period To Complete Business Combination From Closing Of Offering MaximumPeriodToCompleteBusinessCombinationFromClosingOfOffering	P18M
CY2023	mcaau	Threshold Period To Enter Into Agreement For Business Combination ThresholdPeriodToEnterIntoAgreementForBusinessCombination	P18M
CY2023	mcaau	Threshold Period To Consummate Business Combination ThresholdPeriodToConsummateBusinessCombination	P24M
CY2023Q4	mcaau	Redemption Price Per Share RedemptionPricePerShare	10.30
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	236900000
CY2021Q4	mcaau	Underwriters Deferred Discount UnderwritersDeferredDiscount	8050000
CY2023Q4	mcaau	Redemption Price Per Share RedemptionPricePerShare	10.30
CY2023Q4	mcaau	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001
CY2023	mcaau	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000
CY2023	mcaau	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1
CY2023Q1	mcaau	Shareholders Exercised Right To Redeem For Number Of Shares ShareholdersExercisedRightToRedeemForNumberOfShares	10784962
CY2023Q1	mcaau	Amount Removed From Trust Account For Redemption Of Shares AmountRemovedFromTrustAccountForRedemptionOfShares	113000000.0
CY2023Q1	mcaau	Fund Held In Trust Account Per Public Share FundHeldInTrustAccountPerPublicShare	10.48
CY2023Q1	mcaau	Percentage Of Public Shares Redeemed PercentageOfPublicSharesRedeemed	0.469
CY2023Q1	mcaau	Percentage Of Public Shares Outstanding PercentageOfPublicSharesOutstanding	0.531
CY2023Q3	mcaau	Shareholders Exercised Right To Redeem For Number Of Shares ShareholdersExercisedRightToRedeemForNumberOfShares	701973
CY2023Q3	mcaau	Amount Removed From Trust Account For Redemption Of Shares AmountRemovedFromTrustAccountForRedemptionOfShares	7800000
CY2023Q3	mcaau	Fund Held In Trust Account Per Public Share FundHeldInTrustAccountPerPublicShare	11.05
CY2023Q3	mcaau	Percentage Of Public Shares Redeemed PercentageOfPublicSharesRedeemed	0.499
CY2023Q3	mcaau	Percentage Of Public Shares Outstanding PercentageOfPublicSharesOutstanding	0.501
CY2023	mcaau	Total Monthly Payments Deposited TotalMonthlyPaymentsDeposited	1200000
CY2023Q4	mcaau	Redemption Price Per Share RedemptionPricePerShare	10.30
CY2023Q4	mcaau	Redemption Price Per Share RedemptionPricePerShare	10.30
CY2023Q4	mcaau	Redemption Price Per Share RedemptionPricePerShare	10.30
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68536
CY2023Q4	mcaau	Working Capital Deficit WorkingCapitalDeficit	6133742
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	0
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	129271658
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	239430719
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	13406427
CY2023Q4	mcaau	Temporary Equity Proceeds From Initial Public Offering TemporaryEquityProceedsFromInitialPublicOffering	230000000
CY2022Q4	mcaau	Temporary Equity Proceeds From Initial Public Offering TemporaryEquityProceedsFromInitialPublicOffering	230000000
CY2023Q4	mcaau	Temporary Equity Proceeds Allocated To Public Warrants TemporaryEquityProceedsAllocatedToPublicWarrants	6900000
CY2022Q4	mcaau	Temporary Equity Proceeds Allocated To Public Warrants TemporaryEquityProceedsAllocatedToPublicWarrants	6900000
CY2023Q4	mcaau	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	12963555
CY2022Q4	mcaau	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	12963555
CY2023Q4	mcaau	Temporary Equity Redemptions TemporaryEquityRedemptions	120810086
CY2023Q4	mcaau	Fair Value Of Over Allotment Liability FairValueOfOverAllotmentLiability	60000
CY2022Q4	mcaau	Fair Value Of Over Allotment Liability FairValueOfOverAllotmentLiability	60000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	mcaau	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	23000000
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	mcaau	Payable Into Trust Account Current PayableIntoTrustAccountCurrent	600000
CY2023Q4	mcaau	Number Of Payments To Be Made In Trust Account NumberOfPaymentsToBeMadeInTrustAccount	2
CY2023Q4	mcaau	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	3
CY2023Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	2537500
CY2023Q3	mcaau	Percentage Of Interest Rate In Trust Account PercentageOfInterestRateInTrustAccount	0.0460
CY2023Q4	mcaau	Minimum Cash Condition Intended To Cover Expenses MinimumCashConditionIntendedToCoverExpenses	90000000
CY2023Q3	mcaau	Capital Market Advisor Fee CapitalMarketAdvisorFee	4000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	mcaau	Board Of Directors Number Of Classes BoardOfDirectorsNumberOfClasses	3
CY2023	mcaau	Board Of Directors Term BoardOfDirectorsTerm	P3Y
CY2023Q4	mcaau	Board Of Directors Number Of Classes Appointed Each Year BoardOfDirectorsNumberOfClassesAppointedEachYear	1
CY2023Q4	mcaau	Class B Shares Minimum Conversion Ratio To Class ClassBSharesMinimumConversionRatioToClass	1
CY2023Q3	mcaau	Payments Deposited Per Month PaymentsDepositedPerMonth	300000
CY2023Q3	mcaau	Total Monthly Payments Deposited TotalMonthlyPaymentsDeposited	1800000
CY2023Q3	mcaau	Aggregate Payments Deposited For Four Calendar Months AggregatePaymentsDepositedForFourCalendarMonths	1200000

Files In Submission

Name	View Source	Status
0001104659-24-064383-index-headers.html	Edgar Link	pending
0001104659-24-064383-index.html	Edgar Link	pending
0001104659-24-064383.txt	Edgar Link	pending
0001104659-24-064383-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mcaau-20231231.xsd	Edgar Link	pending
mcaau-20231231x10k.htm	Edgar Link	pending
mcaau-20231231xex31d1.htm	Edgar Link	pending
mcaau-20231231xex31d2.htm	Edgar Link	pending
mcaau-20231231xex32d1.htm	Edgar Link	pending
mcaau-20231231xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
mcaau-20231231_cal.xml	Edgar Link	unprocessable
mcaau-20231231_def.xml	Edgar Link	unprocessable
mcaau-20231231_lab.xml	Edgar Link	unprocessable
mcaau-20231231_pre.xml	Edgar Link	unprocessable
mcaau-20231231x10k_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MCAA
Mountain & Co I Acquisition Corp Stock $mcaa

2023 Q4 Form 10-K Financial Statement

#000110465924064383 Filed on May 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCAA Mountain & Co I Acquisition Corp Stock $mcaa

2023 Q4 Form 10-K Financial Statement

#000110465924064383 Filed on May 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCAA
Mountain & Co I Acquisition Corp Stock $mcaa